The announcement marks Malin’s first new asset following its stock exchange debut earlier this year

Malin, an Irish-based company set up by a number of former Elan executives to invest in privately held life science assets, has invested $35 million a(...)

AstraZeneca hopes to boost falling profits through the development of a  new class of lung treatments known as LABA/LAMA drugs, after acquiring US respiratory drug specialist Pearl Therapeutics.

AstraZeneca is to buy US respiratory drug specialist Pearl Therapeutics for up to $1.15 billion (€870 million) as Britain’s second biggest drugmaker (...)